These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

148 related items for PubMed ID: 15231697

  • 1. A tumor suppressor role for thyroid hormone beta receptor in a mouse model of thyroid carcinogenesis.
    Kato Y, Ying H, Willingham MC, Cheng SY.
    Endocrinology; 2004 Oct; 145(10):4430-8. PubMed ID: 15231697
    [Abstract] [Full Text] [Related]

  • 2. Mutant thyroid hormone receptor beta represses the expression and transcriptional activity of peroxisome proliferator-activated receptor gamma during thyroid carcinogenesis.
    Ying H, Suzuki H, Zhao L, Willingham MC, Meltzer P, Cheng SY.
    Cancer Res; 2003 Sep 01; 63(17):5274-80. PubMed ID: 14500358
    [Abstract] [Full Text] [Related]

  • 3. Chromosomal aberrations in cell lines derived from thyroid tumors spontaneously developed in TRbetaPV/PV mice.
    Zimonjic DB, Kato Y, Ying H, Popescu NC, Cheng SY.
    Cancer Genet Cytogenet; 2005 Sep 01; 161(2):104-9. PubMed ID: 16102579
    [Abstract] [Full Text] [Related]

  • 4. Inhibition of phosphatidylinositol 3-kinase delays tumor progression and blocks metastatic spread in a mouse model of thyroid cancer.
    Furuya F, Lu C, Willingham MC, Cheng SY.
    Carcinogenesis; 2007 Dec 01; 28(12):2451-8. PubMed ID: 17660507
    [Abstract] [Full Text] [Related]

  • 5. Alterations in genomic profiles during tumor progression in a mouse model of follicular thyroid carcinoma.
    Ying H, Suzuki H, Furumoto H, Walker R, Meltzer P, Willingham MC, Cheng SY.
    Carcinogenesis; 2003 Sep 01; 24(9):1467-79. PubMed ID: 12869418
    [Abstract] [Full Text] [Related]

  • 6. Marked potentiation of the dominant negative action of a mutant thyroid hormone receptor beta in mice by the ablation of one wild-type beta allele.
    Suzuki H, Zhang XY, Forrest D, Willingham MC, Cheng SY.
    Mol Endocrinol; 2003 May 01; 17(5):895-907. PubMed ID: 12576488
    [Abstract] [Full Text] [Related]

  • 7. Multi-tissue gene-expression analysis in a mouse model of thyroid hormone resistance.
    Miller LD, McPhie P, Suzuki H, Kato Y, Liu ET, Cheng SY.
    Genome Biol; 2004 May 01; 5(5):R31. PubMed ID: 15128445
    [Abstract] [Full Text] [Related]

  • 8. Mice with a mutation in the thyroid hormone receptor beta gene spontaneously develop thyroid carcinoma: a mouse model of thyroid carcinogenesis.
    Suzuki H, Willingham MC, Cheng SY.
    Thyroid; 2002 Nov 01; 12(11):963-9. PubMed ID: 12490073
    [Abstract] [Full Text] [Related]

  • 9. The steroid receptor coactivator-3 is a tumor promoter in a mouse model of thyroid cancer.
    Ying H, Willingham MC, Cheng SY.
    Oncogene; 2008 Jan 31; 27(6):823-30. PubMed ID: 17653082
    [Abstract] [Full Text] [Related]

  • 10. The pituitary tumor-transforming gene promotes angiogenesis in a mouse model of follicular thyroid cancer.
    Kim CS, Ying H, Willingham MC, Cheng SY.
    Carcinogenesis; 2007 May 31; 28(5):932-9. PubMed ID: 17127711
    [Abstract] [Full Text] [Related]

  • 11. PPARgamma insufficiency promotes follicular thyroid carcinogenesis via activation of the nuclear factor-kappaB signaling pathway.
    Kato Y, Ying H, Zhao L, Furuya F, Araki O, Willingham MC, Cheng SY.
    Oncogene; 2006 May 04; 25(19):2736-47. PubMed ID: 16314832
    [Abstract] [Full Text] [Related]

  • 12. Growth activation alone is not sufficient to cause metastatic thyroid cancer in a mouse model of follicular thyroid carcinoma.
    Lu C, Zhao L, Ying H, Willingham MC, Cheng SY.
    Endocrinology; 2010 Apr 04; 151(4):1929-39. PubMed ID: 20133453
    [Abstract] [Full Text] [Related]

  • 13. AKT activation promotes metastasis in a mouse model of follicular thyroid carcinoma.
    Kim CS, Vasko VV, Kato Y, Kruhlak M, Saji M, Cheng SY, Ringel MD.
    Endocrinology; 2005 Oct 04; 146(10):4456-63. PubMed ID: 16002527
    [Abstract] [Full Text] [Related]

  • 14. Regulation of beta-catenin by a novel nongenomic action of thyroid hormone beta receptor.
    Guigon CJ, Zhao L, Lu C, Willingham MC, Cheng SY.
    Mol Cell Biol; 2008 Jul 04; 28(14):4598-608. PubMed ID: 18474620
    [Abstract] [Full Text] [Related]

  • 15. Synergistic signaling of KRAS and thyroid hormone receptor β mutants promotes undifferentiated thyroid cancer through MYC up-regulation.
    Zhu X, Zhao L, Park JW, Willingham MC, Cheng SY.
    Neoplasia; 2014 Sep 04; 16(9):757-69. PubMed ID: 25246276
    [Abstract] [Full Text] [Related]

  • 16. Activation of phosphatidylinositol 3-kinase signaling by a mutant thyroid hormone beta receptor.
    Furuya F, Hanover JA, Cheng SY.
    Proc Natl Acad Sci U S A; 2006 Feb 07; 103(6):1780-5. PubMed ID: 16446424
    [Abstract] [Full Text] [Related]

  • 17. Differential expression of thyroid hormone receptor isoforms dictates the dominant negative activity of mutant Beta receptor.
    Zhang XY, Kaneshige M, Kamiya Y, Kaneshige K, McPhie P, Cheng SY.
    Mol Endocrinol; 2002 Sep 07; 16(9):2077-92. PubMed ID: 12198244
    [Abstract] [Full Text] [Related]

  • 18. Gelsolin: a novel thyroid hormone receptor-beta interacting protein that modulates tumor progression in a mouse model of follicular thyroid cancer.
    Kim CS, Furuya F, Ying H, Kato Y, Hanover JA, Cheng SY.
    Endocrinology; 2007 Mar 07; 148(3):1306-12. PubMed ID: 17170101
    [Abstract] [Full Text] [Related]

  • 19. Novel oncogenic actions of TRbeta mutants in tumorigenesis.
    Guigon CJ, Cheng SY.
    IUBMB Life; 2009 May 07; 61(5):528-36. PubMed ID: 19391168
    [Abstract] [Full Text] [Related]

  • 20. Lack of mutations in the thyroid hormone receptor (TR) alpha and beta genes but frequent hypermethylation of the TRbeta gene in differentiated thyroid tumors.
    Joseph B, Ji M, Liu D, Hou P, Xing M.
    J Clin Endocrinol Metab; 2007 Dec 07; 92(12):4766-70. PubMed ID: 17911173
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.